Hypothesis

Administering Lactobacillus strains at the peak of endogenous vagal tone (early subjective night) will amplify circadian‑dependent Per2 signaling in the enteric nervous system, leading to greater vagal afferent activity, higher HRV, and reduced anxiety compared with administration at trough vagal tone (morning).

Mechanistic Rationale

It's known that circadian clocks in gut epithelial cells regulate Per2 expression, which influences barrier integrity and the release of enterochromaffin‑derived serotonin [[https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1697200/full]]. Lactobacillus metabolites such as indole‑3‑propionic acid and GABA are produced in a rhythm‑sensitive manner and can activate epithelial Per2‑dependent pathways that increase vagal firing [[https://pmc.ncbi.nlm.nih.gov/articles/PMC12766537/]]. When the microbiota‑derived signal coincides with the natural nocturnal rise in vagal tone, the combined effect supra‑additively boosts brainstem nucleus tractus solitarius activity, enhancing HRV and dampening amygdala‑driven anxiety. If given out of phase, the signal doesn't align with the endogenous rhythm and can be blunted or even oppose it, yielding minimal HRV change.

Predictions and Experimental Design

1. HRV Biomarker – Participants receiving the probiotic at 22:00 will show a significant increase in RMSSD and HF power relative to baseline and to a morning‑dose group (08:00) after two weeks (p<0.05, effect size d>0.5).
2. Anxiety Outcomes – Same night‑dose group will exhibit a larger reduction in State‑Trait Anxiety Inventory scores (≥30% drop) than the morning group.
3. Molecular Mediators – Fecal samples will reveal higher indole‑3‑propionic acid and GABA concentrations only in the night‑dose cohort, correlating with Per2 expression in colonic biopsies (r>0.4).
4. Falsifiability – If night‑dose does not produce greater HRV or anxiety improvement than morning‑dose, or if metabolite levels do not differ, the hypothesis is refuted.

A crossover, double‑blind, placebo‑controlled trial with 60 healthy adults stratified by chronotype (MEQ scores) will test these predictions. Each participant receives two 14‑day interventions (night vs. morning L. rhamnosus JB‑1, 10^9 CFU) separated by a 2‑week washout, with HRV recorded via 24‑h Holter, anxiety questionnaires, and metabolomic/fecal sampling at baseline and endpoint.

Potential Outcomes

• Support – Demonstrates timed probiotic dosing as a chronobiotic strategy to harness the gut‑brain axis, providing a mechanistic basis for HRV as a reliable biomarker.
• Refutation – Indicates that vagal‑tone timing does not modulate probiotic efficacy, shifting focus to other modifiers (baseline inflammation, strain‑specific adhesion) and questioning HRV’s sensitivity to short‑term gut‑derived vagal changes.